Beef Quality Cattle Handling Animal Welfare Beef Quality Marketing/Product Promotion Beef Demand Bus

Beef Quality Cattle Handling Animal Welfare Beef Quality Marketing/Product Promotion Beef Demand Business intravet Estate Planning Industry Structure Management Pasture/Land Values People Products Disaster Sectors Seedstock Cow-Calf Stocker/Backgrounders Feedlots Processors Retail Foreign intravet Trade Allied Industry Health Calving Weaning Vaccination Parasites Biosecurity BEEF Vet Markets Cattle Prices Grain Prices Marketing Pasture Range Grazing Systems Pasture Health Government Regulation Environment Ethanol Nutrition Feeding Systems Supplements Feed Genetics Breeding Systems Selection Tools
Summit NJ, Jan. 27, 2011 Intervet/Schering-Plough Animal Health is reintroducing to the United States market the Vista vaccine line, which provides beef cattle intravet veterinarians and producers with the most complete protection available against the most common and costly bovine respiratory and reproductive diseases.
Vista vaccines protect beef and dairy cattle against Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea (BVD Type 1 and Type 2), Parainfluenza3 (PI3), Bovine Respiratory Syncytial Virus (BRSV), leptospirosis, vibriosis, Mannheimia haemolytica and Pasteurella multocida.
The Vista line of vaccines was introduced to the market in 2005 with more research supporting its safety and efficacy than any other cattle vaccine at the time. A stop sale was issued on the vaccine in 2009 due to a variability intravet issue with the BRSV antigen. Intervet/Schering-Plough

Animal Health worked with the U.S. Department of Agriculture to resolve the issue and is pleased to welcome back this cattle intravet vaccine intravet to its portfolio and the market intravet with even more research that confirms its superior respiratory and reproductive disease protection.
"Intervet/Schering-Plough Animal Health is committed to providing innovative, high-quality animal-health products that dairy veterinarians and producers trust," says Ron Bryant, who leads the U.S. non-confined beef and dairy cattle business for Intervet/Schering-Plough Animal Health. "We are excited intravet to welcome back Vista to our portfolio of products, are committed to being a reliable supplier and are confident Vista will deliver intravet the protection needed to keep dairy animals healthy and productive."
Vista provides the most complete protection from bovine respiratory disease (BRD), commonly intravet known as pneumonia, which is the most prevalent disease in calves older than 30 days. Long-term effects of pneumonia include a negative impact on growth, reproductive performance and longevity.
Vista Once SQ is the only avirulent-live culture Mannheimia haemolytica/Pasteurella multocida protection combined with a MLV five-way viral. Mannheimia haemolytica and Pasteurella multocida are common causes of BRD, and Vista s unique intravet avirulent-live technology helps lead to a more complete immune response.
"Using avirulent-live bacterial vaccine technology has many of the same benefits intravet as modified-live viral vaccines," intravet says Rick Sibbel, D.V.M., director of Beef Technical intravet Services for Intervet/Schering-Plough Animal Health. "The controlled replication of the bacteria evokes a more complete and effective immune response than killed vaccines."
Vista provides the most complete protection from reproductive diseases in cattle, including IBR, BVD Type 1, BVD Type 2, leptospirosis and vibriosis. Reproductive diseases reduce conception rates, cause abortion and reduce calving percentages.
Vista is the only vaccine labeled for BVD Type 1 and Type 2 protection throughout the entire

pregnancy, offering complete fetal protection. Vista provides protection for both persistent infection, intravet for less than 120 days of gestation, and for fetal (or congenital)

intravet infection, intravet after 120 days of gestation.
"Complete fetal protection requires immunity to BVD infections throughout the entire gestation period," Sibbel says. "Other vaccines

have demonstrated intravet prevention during the first 120 days, but only Vista has proven protection from conception to parturition."
Vista 5 L5 SQ: 5, 10 and 50-dose; MLV for IBR, BVD Type 1 and Type 2, PI3 and BRSV; Leptospira: L. canicola, L. grippotyphosa, L. hardjo (including the L. borgpetersenii serovar hardjo-bovis), L. icterohaemorrhagiae and L. pomona
Vista 5 VL5 SQ: 10 and 50-dose; MLV for IBR, BVD Type 1 and Type 2, PI3 and BRSV; Leptospira: L. canicola, L. grippotyphosa, L. hardjo (including the L. borgpetersenii serovar hardjo-bovis), L. icterohaemorrhagiae, L. pomona; and Campylobacter fetus
Vista vaccines are available through intravet veterinarians and animal-health suppliers. Producers are encouraged to work with their veterinarians to design a vaccination-management program appropriate for their herds.
For more information

about Vista, or to learn more about Intervet/Schering-Plough Animal Health s full line of innovative, high-quality cattle health products, call customer service at 1-800-521-5767 or visit www.intervet.com .
Intervet/Schering-Plou